Headline: Newborns to oncology patients — CPT code 81121 captures technical laboratory testing for IDH2 gene variants

Lead: CPT code 81121 designates the technical component of molecular testing that detects common changes in the mitochondrial isocitrate dehydrogenase 2 (IDH2) gene. This molecular diagnostic procedure informs diagnosis and treatment selection in conditions where IDH2 mutation status is clinically relevant.

CPT code 81121 represents a targeted genetic test performed by laboratory personnel to identify IDH2 (NADP+) gene variants. The code matters nationally because molecular diagnostics increasingly guide oncology therapeutics, clinical trial eligibility, and precision medicine pathways. Insurers and Medicare routinely evaluate coverage policies and reimbursement for such tests given their impact on treatment decisions and downstream costs.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context, expected site-of-service settings, and coverage landscape considerations. The publication summarizes benchmarking and utilization patterns where available, highlights payment and coding considerations relevant to laboratories and billing staff, and outlines the clinical scenarios in which IDH2 testing is typically performed.

Data not available in the input: associated taxonomies, ICD-10 diagnoses, related codes, and payer-specific coverage rules. The content focuses on national-level code definition, clinical relevance, and payer scope.